8-K: Metagenomi Announces Positive Preclinical Data for Hemophilia A Gene Editing Therapy

Metagenomi's preclinical study of its hemophilia A gene editing therapy, MGX-001, shows durable Factor VIII activity levels in non-human primates over twelve months, supporting its potential as a curative treatment.

Summary

• Metagenomi announced positive twelve-month preclinical data for its hemophilia A gene editing therapy, MGX-001.
• The study, conducted on non-human primates (NHPs), demonstrated durable Factor VIII (FVIII) activity levels.
• Two of the three NHPs showed FVIII activity levels within the normal or near-normal range (82% and 41%) at the twelve-month mark, while the third had levels in the mild hemophilia range (9%).
• The data showed no significant decline in FVIII activity levels from the three to six month period compared to the nine to twelve month period.
• Liver biopsies showed gene integration at a frequency of 0.7% to 2.9%, which correlated with FVIII activity levels.
• The treatment was generally well-tolerated, with only moderate transient elevations in liver transaminases observed following AAV and LNP administration.
• The company is on track for an Investigational New Drug (IND) filing in 2026.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical data with strong indications of efficacy and safety, suggesting a high potential for the therapy. The company is also on track for an IND filing, which is a positive milestone.

Positives

• The study demonstrated durable FVIII activity levels over a twelve-month period in NHPs.
• The majority of NHPs achieved normal or near-normal FVIII activity levels.
• Gene integration was confirmed in liver biopsies, indicating successful gene editing.
• The treatment was generally well-tolerated with no significant adverse effects.
• The results support the potential of MGX-001 as a one-time curative treatment for hemophilia A.
• The company is on track for an IND filing in 2026.

Negatives

• One NHP had FVIII activity levels in the mild hemophilia range (9%) at the twelve-month mark.
• Moderate transient elevations in liver transaminases were observed following AAV and LNP administration.

Risks

• The study is preclinical, and results may not translate to human trials.
• The company is dependent on third-party suppliers.
• The company needs substantial additional funds to continue development.
• There are risks associated with government regulation and intellectual property matters.
• The company faces competition in the gene editing space.

Future Outlook

The company intends to leverage the MGX-001 editing platform to pursue additional therapies for secreted protein disorders and is on track for an IND filing in 2026.

Management Comments

• We are thrilled to achieve this preclinical milestone supporting our recent decision to declare MGX-001 as our development candidate for hemophilia A, said Brian C. Thomas, PhD, CEO and founder of Metagenomi.
• Our goal for MGX-001 is to provide a one-time, curative treatment for adults and children with hemophilia A.
• I am encouraged by the preclinical progress in the genome editing space to potentially provide a new path to a one-time, curative treatment option for both adults and children in hemophilia A in the future, said Dr. Glenn Pierce, member of the Metagenomi Scientific Advisory Board.

Industry Context

The announcement highlights the potential of gene editing to disrupt the treatment of hemophilia A, which has seen transformative changes over the past 60 years. The company is aiming to address the limitations of current gene therapies, which have struggled to achieve long-term persistence of FVIII activity levels.

Comparison to Industry Standards

• The study's focus on durable FVIII activity levels addresses a key challenge in the hemophilia A gene therapy space, where long-term persistence has been difficult to achieve.
• Companies like BioMarin Pharmaceutical and Sangamo Therapeutics have also been developing gene therapies for hemophilia A, but Metagenomi's approach focuses on site-specific gene integration, which could offer a more durable solution.
• The reported FVIII activity levels in the NHPs, with two animals achieving normal or near-normal levels, are promising compared to some previous gene therapy trials that have shown variable and sometimes declining FVIII expression over time.
• The use of a novel Metagenomi nuclease and associated guide RNA targeting the albumin gene's first intron is a unique approach compared to other gene editing strategies.

Stakeholder Impact

• The positive preclinical data is likely to be well-received by shareholders.
• The potential for a one-time curative treatment could significantly improve the lives of patients with hemophilia A.
• The company's progress could attract further investment and partnerships.

Next Steps

• The company will host a conference call on September 4, 2024, to discuss the data.
• The company is on track for an IND filing in 2026.
• The company intends to leverage the MGX-001 editing platform to pursue additional therapies for secreted protein disorders.

Key Dates

Keywords

gene editing, hemophilia A, MGX-001, Factor VIII, preclinical study, gene therapy, Metagenomi, non-human primates, AAV, LNP, IND filing